Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Picard Medical, Inc. ( (PMI) ) just unveiled an update.
On November 19, 2025, Picard Medical, Inc. announced that its subsidiary, SynCardia Systems LLC, successfully completed the first in vivo implantations of the Emperor Total Artificial Heart. This milestone marks a significant advancement in artificial heart technology, reinforcing Picard Medical’s leadership in the field. The Emperor TAH demonstrated stable and efficient performance in pre-clinical models, closely mimicking natural heart functions, and is expected to expand the total artificial heart market by offering a fully implantable system with enhanced usability and efficiency.
More about Picard Medical, Inc.
Picard Medical, Inc., headquartered in Tucson, Arizona, is the parent company of SynCardia Systems, LLC. SynCardia is a leader in total artificial heart technology, offering the only commercially available total artificial heart for patients with end-stage heart failure. The SynCardia Total Artificial Heart is FDA and Health Canada approved, with over 2,100 implants performed globally.
Average Trading Volume: 2,482,124
Find detailed analytics on PMI stock on TipRanks’ Stock Analysis page.